<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pak J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Pak J Med Sci</journal-id><journal-title-group><journal-title>Pakistan Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1682-024X</issn><issn pub-type="epub">1681-715X</issn><publisher><publisher-name>Professional Medical Publications</publisher-name><publisher-loc>Pakistan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27182262</article-id><article-id pub-id-type="pmc">4859045</article-id><article-id pub-id-type="publisher-id">PJMS-32-462</article-id><article-id pub-id-type="doi">10.12669/pjms.322.8836</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Clinical efficacy of tiotropium in children with asthma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Juan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Long</surname><given-names>Zhen</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Xiaoqin</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Shu</surname><given-names>Junhua</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Juan Huang, Department of Pediatric Internal Medicine, Hubei Maternal and Child Health Care Hospital, Wuhan 430072, China</aff><aff id="aff2"><label>2</label>Ying Chen, Department of Pediatric Internal Medicine, Hubei Maternal and Child Health Care Hospital, Wuhan 430072, China</aff><aff id="aff3"><label>3</label>Zhen Long, Department of Pediatric Internal Medicine, Hubei Maternal and Child Health Care Hospital, Wuhan 430072, China</aff><aff id="aff4"><label>4</label>Xiaoqin Zhou, Department of Pediatric Internal Medicine, Hubei Maternal and Child Health Care Hospital, Wuhan 430072, China</aff><aff id="aff5"><label>5</label>Junhua Shu, Department of Pediatric Internal Medicine, Hubei Maternal and Child Health Care Hospital, Wuhan 430072, China</aff><author-notes><corresp id="cor1">
Correspondence: Zhen Long, E-mail: <email xlink:href="hjdoccn@163.com">hjdoccn@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2016</year></pub-date><volume>32</volume><issue>2</issue><fpage>462</fpage><lpage>465</lpage><history><date date-type="received"><day>21</day><month>8</month><year>2015</year></date><date date-type="rev-recd"><day>15</day><month>2</month><year>2016</year></date><date date-type="rev-recd"><day>16</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Pakistan Journal of Medical Sciences</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objective:</title><p>To investigate the clinical efficacy of tiotropium in children with asthma.</p></sec><sec id="st2"><title>Methods:</title><p>Eighty children with newly diagnosed moderate persistent asthma were enrolled into this study. The children were randomly assigned to the fluticasone propionate aerosol group or the fluticasone propionate aerosol plus tiotropium group for 12 weeks.</p></sec><sec id="st3"><title>Results:</title><p>Lung function was significantly improved in both groups at 4, 8, and 12 weeks compared with baseline (<italic>P</italic> &#x0003c; 0.01). Moreover, lung function was significantly improved in the tiotropium group compared with the control group (<italic>P</italic> &#x0003c; 0.05). However, there was no significant difference in the incidence of severe asthma between the two groups (36.3% and 26.8%, respectively; <italic>P</italic> &#x0003e; 0.05). Compared with the control group, the number of days and frequency of short-acting beta2-adrenoceptor agonist use was significantly reduced in the tiotropium group (<italic>P</italic> &#x0003c; 0.05). Awakenings during the night were also significantly decreased (<italic>P</italic> &#x0003c; 0.00). There were no severe adverse reactions in either of the study groups.</p></sec><sec id="st4"><title>Conclusion:</title><p>Tiotropium could significantly improve lung function, reduce the use of short-acting beta2-adrenoceptor agonists, and improve sleep in children with asthma. Furthermore, few adverse reactions were reported.</p></sec></abstract><kwd-group><title>KEY WORDS</title><kwd>Anticholinergic agent</kwd><kwd>Asthma</kwd><kwd>Children</kwd><kwd>Tiotropium</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Asthma is a common chronic inflammatory disorder of the airways which is associated with airway hyperresponsiveness, smooth muscle spasm, and airflow obstruction. Over recent years, the global rates of asthma have increased significantly. In USA, about 7 million children and adolescents suffer from asthma,<xref rid="ref1" ref-type="bibr">1</xref> in the UK, one in every seven children aged 2-15 has asthma symptoms requiring regular treatment<xref rid="ref2" ref-type="bibr">2</xref> and in China, about 232 in every 10 thousand children under 14 years in the urban has asthma, the rate is more higher than 10 years ago (which is 154 in every 10 thousand).<xref rid="ref3" ref-type="bibr">3</xref></p><p>Inhaled glucocorticoids are considered the first-line treatment for patients with asthma.<xref rid="ref4" ref-type="bibr">4</xref>, <xref rid="ref5" ref-type="bibr">5</xref> But many patients taking an inhaled glucocorticoid are inadequately controlled which represents a significant healthcare concern.<xref rid="ref6" ref-type="bibr">6</xref>, <xref rid="ref7" ref-type="bibr">7</xref> In combination with inhaled long-acting beta2-adrenoceptor agonists (LABAs) can improve asthma control in children.<xref rid="ref8" ref-type="bibr">8</xref> However, the long-term use of LABAs is associated with tolerance to the protective effects on the bronchi and an increased risk of fatal asthma exacerbations. The US Food and Drug Administration (FDA) have concerns regarding the safety of LABAs and they recommend that patients discontinue LABAs upon control of asthma symptoms.<xref rid="ref9" ref-type="bibr">9</xref>, <xref rid="ref10" ref-type="bibr">10</xref> So alternative medications for bronchospasm relief are required.</p><p>Tiotropium is a long-acting anticholinergic bronchodilator<xref rid="ref11" ref-type="bibr">11</xref> and many researchers consider the effect of tiotropiu is superior to that of LABA,<xref rid="ref12" ref-type="bibr">12</xref>, <xref rid="ref13" ref-type="bibr">13</xref> which was effective in COPD.<xref rid="ref14" ref-type="bibr">14</xref>, <xref rid="ref15" ref-type="bibr">15</xref> Recently several studies have demonstrated that tritropium is effective in the treatment of asthma in adults<xref rid="ref16" ref-type="bibr">16</xref>, <xref rid="ref17" ref-type="bibr">17</xref> and adolescents.<xref rid="ref18" ref-type="bibr">18</xref> Here we report our data on evaluating the efficacy and safety of tritropium in children. We observed the effects on lung function, exacerbation frequency, awakening during the night, and other end pints during a 12-week period in children with asthma.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><p>Eighty children aged 6-14 years (mean: 10.2&#x000b1;3.6 years) who were diagnosed with moderate persistent asthma in our hospital between December 2013 and December 2014 were enrolled into this study. All the children conformed to the 2008 diagnostic criteria of childhood asthma from the national pediatric asthma association. Eligible children had not received systemic corticosteroids, beta2-adrenoceptor agonists, or cholinergic receptor antagonists for four weeks before enrolment into the study. None of the children had contraindications for corticosteroids use, hypertension, heart disease, or glaucoma. This study was conducted in accordance with the declaration of Helsinki. Approval from the Ethics Committee of Hubei Maternal and Child Health Care Hospital. Written informed consent was obtained from all participants&#x02019; guardians. Additionally, the children could use the metered dose inhaler and inhalation system for tiotropium correctly.</p><p>The 80 children were randomly assigned to receive either 125 &#x003bc;g fluticasone propionate aerosol twice daily plus placebo once daily (control group), or 125 &#x003bc;g fluticasone propionate aerosol twice daily plus 18 &#x003bc;g tiotropium dry-powder inhaler once daily (treatment group). The study duration was 12 weeks. If the children experienced acute asthma symptoms during the study, short-acting beta2-adrenoceptor agonists, such as 100 &#x003bc;g albuterol aerosol, were permitted as rescue medication. There were no significant differences between the study groups at baseline in age, sex, body mass index (BMI), forced expiratory volume in one second (FEV<sub>1</sub>%), forced vital capacity (FVC), and peak expiratory flow (PEF%) (<xref ref-type="table" rid="T1">Table-I</xref>). Tiotropium dry-powder capsules (18 &#x003bc;g) were provided by Si Lihua, Boehringer Ingelheim Company, lot number: 301564; fluticasone propionate aerosol (125 &#x003bc;g) was provided by GSK Company, lot number: YJ0225; and albuterol aerosol (100 &#x003bc;g) was provided by Wan Tuolin, GSK Company, lot number: BB0226.</p><table-wrap id="T1" position="float"><label>Table-I</label><caption><p>Comparisons of BMI, age and lung function between two groups (&#x003c7;&#x00304;&#x000b1;s).</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Groups</th><th align="left" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">Male: Female</th><th align="left" rowspan="1" colspan="1">BMI</th><th align="left" rowspan="1" colspan="1">Age</th><th align="left" rowspan="1" colspan="1">FVC(L)</th><th align="left" rowspan="1" colspan="1">PEF%</th><th align="left" rowspan="1" colspan="1">FEV<sub>1</sub>%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="left" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">24:16</td><td align="left" rowspan="1" colspan="1">18.2&#x000b1;3.0</td><td align="left" rowspan="1" colspan="1">10.1&#x000b1;4.8</td><td align="left" rowspan="1" colspan="1">1.55&#x000b1;0.56</td><td align="left" rowspan="1" colspan="1">68.57&#x000b1;3.42</td><td align="left" rowspan="1" colspan="1">67.41&#x000b1;8.51</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="left" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">25:15</td><td align="left" rowspan="1" colspan="1">18.5&#x000b1;3.1</td><td align="left" rowspan="1" colspan="1">9.3&#x000b1;5.2</td><td align="left" rowspan="1" colspan="1">1.53&#x000b1;0.47</td><td align="left" rowspan="1" colspan="1">69.88&#x000b1;3.55</td><td align="left" rowspan="1" colspan="1">67.31&#x000b1;7.32</td></tr></tbody></table></table-wrap><sec id="sec2-1"><title>Lung function testing</title><p>Lung function testing was performed using a Jaeger MasterScreen pulmonary function testing system (Germany) to examine the tidal breathing flow volume curve at weeks 0 (baseline), 4, 8, &#x00026; 12. Lung function tests included FEV<sub>1</sub>%, FVC, and PEF.</p></sec><sec id="sec2-2"><title>Incidence of severe asthma</title><p>Severe asthma was defined as an exacerbation that required treatment with oral corticosteroids or hospitalization, or where lung function was reduced by 30% compared to baseline. If severe asthma occurred more than twice within the 12-week study period, patients were withdrawn from the study. The frequency of use and number of days of use of short-acting beta2-adrenoceptor agonists were recorded. Night-time awakenings were also recorded.</p></sec><sec id="sec2-3"><title>Statistical analysis</title><p>Statistical analysis was performed using SPSS 10.0 software. The results are presented as mean&#x000b1;SD. A paired t-test was used to analyze count data, and a chi-square test was used to analyze between-group probability. A p-value of &#x0003c;0.05 was considered statistically significant.</p></sec><sec id="sec2-4"><title>Inclusion Criteria</title><p>1. Newly diagnosed moderate persistent asthma; 2. Can use the HandiHaler properly; 3. Without use of any glucocorticoid within 4 weeks and without use of any beta2-adrenoceptor agonists within one weeks; 4. No hormone contraindications.</p></sec><sec id="sec2-5"><title>Exclusion Criteria</title><p>Those who has heart disease, lung infection disease, glaucoma or other complications.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>Two children in each of the study groups were withdrawn from the study following &#x0003e;2 severe asthma exacerbations. Therefore, four cases were not included in the statistical analysis. As shown in <xref ref-type="table" rid="T1">Table-I</xref>, there were no significant differences for BMI, age, and lung function between the 2 groups (<italic>P</italic> &#x0003e; 0.05).</p><p>The FEV<sub>1</sub>%, FVC, and PEF% of patients in both groups were significantly improved at weeks 4, 8, and 12 compared to baseline (<italic>P</italic> &#x0003c; 0.01; <xref ref-type="table" rid="T2">Table-II</xref>). Moreover, the improvement in lung function in the treatment group was significantly greater than in the control group (FEV<sub>1</sub>% at week 12 and FVC at week 8 <italic>P</italic> &#x0003c; 0.05, all other indicators <italic>P</italic> &#x0003c; 0.01).</p><table-wrap id="T2" position="float"><label>Table-II</label><caption><p>Changes of FEV1%, FVC and PEF% before and after treatment in two groups (&#x003c7;&#x00304;&#x000b1;s).</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="3" valign="top" colspan="1"><italic>Groups</italic></th><th align="center" rowspan="3" valign="top" colspan="1"><italic>Case</italic></th><th align="center" colspan="3" rowspan="1"><italic>FEV<sub>1</sub>%</italic></th><th align="center" colspan="3" rowspan="1"><italic>FVC(L)</italic></th><th align="center" colspan="3" rowspan="1"><italic>PEF%</italic></th></tr><tr><th align="left" colspan="9" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1"><italic>4<sup>th</sup> week</italic></th><th align="center" rowspan="1" colspan="1"><italic>8<sup>th</sup> week</italic></th><th align="center" rowspan="1" colspan="1"><italic>12<sup>th</sup> week</italic></th><th align="center" rowspan="1" colspan="1"><italic>4<sup>th</sup> week</italic></th><th align="center" rowspan="1" colspan="1"><italic>8<sup>th</sup> week</italic></th><th align="center" rowspan="1" colspan="1"><italic>12<sup>th</sup> week</italic></th><th align="center" rowspan="1" colspan="1"><italic>4<sup>th</sup> week</italic></th><th align="center" rowspan="1" colspan="1"><italic>8<sup>th</sup> week</italic></th><th align="center" rowspan="1" colspan="1"><italic>12<sup>th</sup> week</italic></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="left" valign="top" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">73.91&#x000b1;5.66<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">82.34&#x000b1;5.02<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">87.53&#x000b1;5.76<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">1.63&#x000b1;0.47<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">1.70&#x000b1;0.51<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">1.80&#x000b1;0.59<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">77.39&#x000b1;3.56<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">81.63&#x000b1;4.76<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup></td><td align="center" rowspan="1" colspan="1">86.35&#x000b1;3.65<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment</td><td align="left" valign="top" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">79.56&#x000b1;7.01<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref><xref ref-type="table-fn" rid="t2f3">#</xref></sup></td><td align="center" rowspan="1" colspan="1">87.44&#x000b1;6.74<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref><xref ref-type="table-fn" rid="t2f3">#</xref></sup></td><td align="center" rowspan="1" colspan="1">91.61&#x000b1;5.73<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref><xref ref-type="table-fn" rid="t2f2">*</xref></sup></td><td align="center" rowspan="1" colspan="1">1.87&#x000b1;0.42<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref><xref ref-type="table-fn" rid="t2f2">*</xref></sup></td><td align="center" rowspan="1" colspan="1">1.95&#x000b1;0.48<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref><xref ref-type="table-fn" rid="t2f2">*</xref></sup></td><td align="center" rowspan="1" colspan="1">2.42&#x000b1;0.55<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref><xref ref-type="table-fn" rid="t2f3">#</xref></sup></td><td align="center" rowspan="1" colspan="1">80.0&#x000b1;3.68<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref><xref ref-type="table-fn" rid="t2f3">#</xref></sup></td><td align="center" rowspan="1" colspan="1">85.52&#x000b1;3.9<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref><xref ref-type="table-fn" rid="t2f3">#</xref></sup></td><td align="center" rowspan="1" colspan="1">89.67&#x000b1;4.14<break/><sup><xref ref-type="table-fn" rid="t2f1">&#x025b2;</xref><xref ref-type="table-fn" rid="t2f3">#</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="t2f1"><label>&#x025b2;</label><p>vs before the treatment <italic>P</italic> &#x0003c; 0.01;</p></fn><fn id="t2f2"><label>*</label><p>vs. control group <italic>P</italic> &#x0003c; 0.05,</p></fn><fn id="t2f3"><label>#</label><p><italic>P</italic> &#x0003c; 0.01</p></fn></table-wrap-foot></table-wrap><p>The incidence of severe asthma was 36.8% (n = 14/38) in the control group and 26.3% (n = 10/38) in the treatment group, but the difference between the two groups was not significant (&#x003c7;<sup>2</sup> = 0.54, <italic>P</italic> &#x0003e; 0.05). Two patients who presented with severe asthma in each of the study groups were withdrawn from the study.</p><p>The frequency and number of days of use of on-demand short-acting beta2-adrenoceptor agonists were significantly reduced in the treatment group compared to the control group (<italic>P</italic> &#x0003c; 0.05; <xref ref-type="table" rid="T3">Table-III</xref>). Furthermore, significantly fewer night-time awakenings were reported in the treatment group compared to the control group (<italic>P</italic> &#x0003c; 0.00).</p><table-wrap id="T3" position="float"><label>Table-III</label><caption><p>Comparisons of frequency and days of use of short acting beta 2 receptor agonist on demand and awakening days during the night (&#x003c7;&#x00304;&#x000b1;s).</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Groups</th><th align="center" rowspan="1" colspan="1">Cases</th><th align="left" rowspan="1" colspan="1">Frequency</th><th align="left" rowspan="1" colspan="1">Days</th><th align="center" rowspan="1" colspan="1">Awakening days during the night</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="center" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">0.65&#x000b1;0.34</td><td align="left" rowspan="1" colspan="1">42.1&#x000b1;16.5</td><td align="center" rowspan="1" colspan="1">45.1&#x000b1;10.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="center" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">0.51&#x000b1;0.23<xref ref-type="table-fn" rid="t3f1">*</xref></td><td align="left" rowspan="1" colspan="1">32.9&#x000b1;14.3<xref ref-type="table-fn" rid="t3f1">*</xref></td><td align="center" rowspan="1" colspan="1">28.4&#x000b1;6.9<xref ref-type="table-fn" rid="t3f2">**</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Vs. control group</p></fn><fn id="t3f1"><label>*</label><p>P &#x0003c; 0.05,</p></fn><fn id="t3f2"><label>**</label><p>P &#x0003c; 0.0.</p></fn></table-wrap-foot></table-wrap><sec id="sec2-6"><title>Adverse reactions</title><p>In the treatment group, there were three reports of adverse reactions. All three patients presented with xerostomia and throat discomfort; however, the symptoms were relieved when the children were given more water and instructed to gargle water after administration of the medication. There were 2 adverse reactions reported in the control group. One patient presented with hoarseness, and another presented with thrush, which was successfully treated with myclin and oral nursing. There were no reports of hypertension, tachycardia, or glaucoma in either of the study groups.</p></sec></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>FEV1%, FVC and PEF% are the standard parameter of lung functions. Our results show that, inhaled corticosteroids can improve the lung function of both the control and treatment groups, the result was the same with Pauwels.<xref rid="ref19" ref-type="bibr">19</xref> When added with tiotropium the lung function of treatment group was improved better than placebo. The result should be connected with tiotropium&#x02019;s subtype selectivity.<xref rid="ref20" ref-type="bibr">20</xref> Vogelberg&#x02019;s nearest study had demonstrated similar effects on children, although the end point was not the same with us.<xref rid="ref21" ref-type="bibr">21</xref></p><p>Awakening during the night is an important factor that affects quality of life in all patients with asthma, including children. A large-scale investigation by Warvik<xref rid="ref22" ref-type="bibr">22</xref> found that 39% of patients with asthma were woken every night due to symptoms, and 74% of patients reported awakening at night at least once a week. Furthermore, 70% of deaths due to asthma happen at night during sleep. Our study found that the tiotropium can reduce the frequency and the days of using the short-acting beta2-adrenoceptor agonists and also reduce the awakening days during the night. The reason may be that the parasympathetic nervous system is an important mechanism in nocturnal asthma symptoms<xref rid="ref23" ref-type="bibr">23</xref> and the long half-life of tiotropium which is nearly 35 hours and the efficacy can last for a whole day.<xref rid="ref24" ref-type="bibr">24</xref> Vogelberg&#x02019;s research had not mentioned it.<xref rid="ref21" ref-type="bibr">21</xref></p><p>Some studies show that the addition of tiotropium can significantly reduced the risk of episodes of the worsening. Our study showed the incidence of severe asthma was lower in the treatment group than in the control group, but the difference between the two groups was not significant. Therefore, a beneficial effect of tiotropium on the risk of severe asthma could not be proved. We think there may be other causal factors of severe asthma exacerbations, for example, allergic rhinitis and nasosinusitis, can complicate treatment.<xref rid="ref25" ref-type="bibr">25</xref></p><p>In conclusion, tiotropium, a long-acting cholinergic receptor antagonist, could significantly improve lung function, reduce the need for on-demand short-acting beta2-adrenoceptor agonists, and improve nocturnal symptoms in children with asthma. Furthermore, tiotropium was associated with few adverse reactions in this patient group. These advantages indicate that tiotropium could be a promising prospect for the future for the treatment of asthma in children.</p></sec></body><back><ack><title>ACKNOWLEDGEMENT</title><p>Natural Science Funding of Science and Technology Department of Hubei Province: The efficacy and safety of the anticholinergic drugs-tiptropium in children with asthma (2013CFB048).</p></ack><fn-group><fn fn-type="other"><p><bold><italic>Declaration of interest:</italic></bold> All the authors declare that they have no conflicts of interest.</p></fn></fn-group><sec id="sec1-5"><title/><sec id="sec2-7"><title>Author&#x02019;s Contributions</title><p><bold><italic>JH:</italic></bold> concept, analysis of data, writing this paper and final approval of the manuscript.</p><p><bold><italic>YC:</italic></bold> Analysis of data, writing and revision of the article.</p><p><bold><italic>ZL:</italic></bold> Designed this study, drafting the article, revising it critically for important intellectual content.</p><p><bold><italic>XZ:</italic></bold> Collection, analysis of data and interpretation.</p><p><bold><italic>JS:</italic></bold> Collecting of data and final approval of the manuscript.</p></sec></sec><ref-list><title>REEFERNCES</title><ref id="ref1"><label>1</label><element-citation publication-type="webpage"><collab>2011 National Health Interview Survey (NHIS) Date. 2011 Lifetime Asthma, Current Asthma, Asthma Attacks among those with Current Asthma</collab><comment><uri xlink:type="simple" xlink:href="http://www.cdc.gov/asthma/nhis/2011/date.htm">http://www.cdc.gov/asthma/nhis/2011/date.htm</uri></comment></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="webpage"><collab>Lung health in Europe: facts and figures</collab><comment><uri xlink:type="simple" xlink:href="http://www.europeanlung.org/assets/files/en/publications/lung-health-in-europe-facts-and-figures-web-vfour.pdf">http://www.europeanlung.org/assets/files/en/publications/lung-health-in-europe-facts-and-figures-web-vfour.pdf</uri></comment></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><collab>National Cooperative Group of Pediatric Asthma, Chinese Center for Disease Control Environmental Health and Related Product Safety. Third Nationwide survey of childhood asthma in urban areas of China</collab><source>Chinese Journal of Pediatrics</source><year>2013</year><volume>51</volume><issue>10</issue><fpage>729</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">24406223</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="book"><collab>Global Initiative for Astham</collab><source>Global strategy for asthma management and prevention</source><year>1995</year><publisher-loc>Washington DC</publisher-loc><publisher-name>National Heart. Lung, and Blood Institute</publisher-name><fpage>9</fpage><comment>Publication no.95-3659</comment></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erika</surname><given-names>VM</given-names></name><name><surname>Jeffrey</surname><given-names>M</given-names></name><name><surname>Drazen</surname><given-names>A</given-names></name></person-group><article-title>Patient with Asthma Seeks Medical Advice in 1828 1928, and 2012</article-title><source>N Engl J Med</source><year>2012</year><volume>9</volume><fpage>825</fpage><lpage>827</lpage></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonathan</surname><given-names>M</given-names></name><name><surname>Haley</surname><given-names>K</given-names></name><name><surname>Lynne</surname><given-names>M</given-names></name><name><surname>Michelle</surname><given-names>L</given-names></name><name><surname>Dara</surname><given-names>S</given-names></name><name><surname>Kimberly</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Prediction of peak flow values followed by feedback improveds perception of lung function and adherence to inhaled corticosteroids in children with asthma</article-title><source>Thorax</source><year>2012</year><volume>67</volume><fpage>1040</fpage><lpage>1045</lpage><pub-id pub-id-type="pmid">23154987</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>AH</given-names></name><name><surname>Gilsenan</surname><given-names>AW</given-names></name><name><surname>Stanford</surname><given-names>RH</given-names></name><name><surname>William</surname><given-names>L</given-names></name><name><surname>Ryan</surname><given-names>Z</given-names></name><name><surname>Hector</surname><given-names>O</given-names></name><etal/></person-group><article-title>Status of asthma control in pediatric primary care: results from the pediatric Asthma Control Characteristics and Prevalence Survey Study(ACCESS)</article-title><source>J Pediatr</source><year>2010</year><volume>157</volume><fpage>276</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">20472251</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodzenta-Lukaszyk</surname><given-names>A</given-names></name><name><surname>van Noord</surname><given-names>J</given-names></name><name><surname>Schr&#x000f6;der-Babo</surname><given-names>W</given-names></name><name><surname>McAulay</surname><given-names>K</given-names></name><name><surname>McIver</surname><given-names>T</given-names></name></person-group><article-title>Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial</article-title><source>Curr Med Res Opin</source><year>2013</year><volume>29</volume><issue>5</issue><fpage>579</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">23368897</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draze</surname><given-names>JM</given-names></name><name><surname>O&#x02019;Byrne</surname><given-names>PM</given-names></name></person-group><article-title>Risks of long-acting bata-agonists in acheving asthma control</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>1671</fpage><lpage>1672</lpage><pub-id pub-id-type="pmid">19369675</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Rockville</surname></name></person-group><source>Food and drug administration: Long-acting beta agonist (LABA) information [EB/OL] [2013-03-10]</source><comment><uri xlink:type="simple" xlink:href="http://www.fda.gov/Drug/Drugsafty/Informationbydrugclass/ucm199565.html">http://www.fda.gov/Drug/Drugsafty/Informationbydrugclass/ucm199565.html</uri></comment></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Belvisi</surname><given-names>MG</given-names></name><name><surname>Mak</surname><given-names>JC</given-names></name><name><surname>Haddad</surname><given-names>EB</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>B</given-names></name></person-group><article-title>Tritropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease</article-title><source>Life Sci</source><year>1995</year><volume>56</volume><issue>11-12</issue><fpage>853</fpage><lpage>859</lpage><pub-id pub-id-type="pmid">10188785</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>ED</given-names></name><name><surname>Kornmann</surname><given-names>O</given-names></name><name><surname>Schmidt</surname><given-names>P</given-names></name><name><surname>Pivovarova</surname><given-names>A</given-names></name><name><surname>Engel</surname><given-names>M</given-names></name><name><surname>Fabbri</surname><given-names>LM</given-names></name></person-group><article-title>Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma</article-title><source>J Allergy Clin Immunol</source><year>2011</year><volume>128</volume><issue>2</issue><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">21807250</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>ME</given-names></name><name><surname>Kunselman</surname><given-names>SJ</given-names></name><name><surname>Chinchilli</surname><given-names>VM</given-names></name><name><surname>Bleeckeret</surname><given-names>E</given-names></name><name><surname>Boushey</surname><given-names>HA</given-names></name><name><surname>Calhoun</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthama (LARGE trial): A genotype-stratified, randomized, placebo-controlled, crossover trial</article-title><source>Lancet</source><year>2009</year><volume>374</volume><issue>9703</issue><fpage>1754</fpage><lpage>1764</lpage><pub-id pub-id-type="pmid">19932356</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Short</surname><given-names>PM</given-names></name><name><surname>Williamson</surname><given-names>PA</given-names></name><name><surname>Elder</surname><given-names>DH</given-names></name><name><surname>Lipworth</surname><given-names>SI</given-names></name><name><surname>Schembri</surname><given-names>S</given-names></name><name><surname>Lipworth</surname><given-names>BJ</given-names></name></person-group><article-title>The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting bete-agonist therapy in COPD</article-title><source>Chest</source><year>2012</year><volume>141</volume><issue>1</issue><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">21799028</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tashkin</surname><given-names>DP</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Stephen</surname><given-names>S</given-names></name><name><surname>Deborah</surname><given-names>B</given-names></name><name><surname>Steven</surname><given-names>K</given-names></name><name><surname>Shailendra</surname><given-names>M</given-names></name><etal/></person-group><article-title>A 4-year trial of tiotropium in chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>1543</fpage><lpage>1554</lpage><pub-id pub-id-type="pmid">18836213</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerstjens</surname><given-names>HAM</given-names></name><name><surname>Disse</surname><given-names>B</given-names></name><name><surname>Schroder-Bantje</surname><given-names>W</given-names></name><name><surname>Bantje</surname><given-names>TA</given-names></name><name><surname>Martina</surname><given-names>G</given-names></name><name><surname>Ralf</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial</article-title><source>J Allergy Clin Immunol</source><year>2011</year><volume>128</volume><fpage>308</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">21636120</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Moroni-Zentgraf</surname><given-names>P</given-names></name><name><surname>Ablinger</surname><given-names>O</given-names></name><name><surname>Hollaenderova</surname><given-names>Z</given-names></name><name><surname>Unseld</surname><given-names>A</given-names></name><name><surname>Engel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tiotropium Respimat in asthma: a double-blind, randomized, dose-ranging study in adult patients with moderate asthma</article-title><source>Respir Res</source><year>2014</year><volume>15</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24397246</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christian</surname><given-names>V</given-names></name><name><surname>Michael</surname><given-names>E</given-names></name><name><surname>Petra</surname><given-names>MZ</given-names></name><name><surname>Ralf</surname><given-names>S</given-names></name><name><surname>John</surname><given-names>D</given-names></name><name><surname>Katja</surname><given-names>N</given-names></name><etal/></person-group><article-title>Tiotropium in ashma adolenscents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study</article-title><source>Respir Med</source><year>2014</year><volume>161</volume><fpage>1268</fpage><lpage>1279</lpage></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauwels</surname><given-names>RA</given-names></name><name><surname>Lofdahl</surname><given-names>CG</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><name><surname>Tattersfield</surname><given-names>AE</given-names></name><name><surname>O&#x02019;Byrne</surname><given-names>P</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Effect of inhaled formoterol and budesonide on exacerbarations of asthma</article-title><source>N Engl J Med</source><year>1997</year><volume>337</volume><issue>20</issue><fpage>1405</fpage><lpage>1411</lpage><pub-id pub-id-type="pmid">9358137</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Littner</surname><given-names>MR</given-names></name><name><surname>Ilowite</surname><given-names>JS</given-names></name><name><surname>Tashkin</surname><given-names>DP</given-names></name><name><surname>Friedman</surname><given-names>M</given-names></name><name><surname>Serby</surname><given-names>CW</given-names></name><name><surname>Menjoge</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Long-acting bronchodilation witlI once-daily dosing of tiotropium (Spiriva) in stable chrenic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2000</year><volume>161</volume><fpage>1136</fpage><lpage>1142</lpage><pub-id pub-id-type="pmid">10764302</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelberg</surname><given-names>C</given-names></name><name><surname>Moroni-Zentgraf</surname><given-names>P</given-names></name><name><surname>Sigmund</surname><given-names>R</given-names></name><name><surname>Hamelmann</surname><given-names>E</given-names></name><name><surname>Engel</surname><given-names>M</given-names></name><name><surname>Szefler</surname><given-names>S</given-names></name></person-group><article-title>A randomised dose-ranging study of tiotropium Respimat<sup>&#x000ae;</sup> in children with symptomatic asthma despite inhaled corticosteroids</article-title><source>Respiratory Res</source><year>2015</year><volume>16</volume><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner-Warwick</surname><given-names>M</given-names></name></person-group><article-title>Epidemilogy of nocturnal asthma</article-title><source>Am J Med</source><year>1988</year><volume>85(1B)</volume><fpage>6</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">3400687</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>JF</given-names></name><name><surname>Pearson</surname><given-names>SB</given-names></name><name><surname>Dean</surname><given-names>HG</given-names></name></person-group><article-title>Parasympathetic nervous system in nocturnal asthma</article-title><source>Br Med J. (Clin Res Ed)</source><year>1988</year><volume>296</volume><issue>6634</issue><fpage>1427</fpage><lpage>1429</lpage></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Mahler</surname><given-names>DA</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Wanner</surname><given-names>A</given-names></name><name><surname>San</surname><given-names>PG</given-names></name><name><surname>ZuWallack</surname><given-names>RL</given-names></name><etal/></person-group><article-title>A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>2002</year><volume>19</volume><issue>2</issue><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">11866001</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Cauwenberge</surname><given-names>PV</given-names></name><name><surname>Khaltaev</surname><given-names>N</given-names></name></person-group><article-title>Allergic rhinitis and its impact on asthma</article-title><source>J Allergy Clin Immunol</source><year>2001</year><volume>108</volume><fpage>S147</fpage><lpage>S334</lpage><pub-id pub-id-type="pmid">11707753</pub-id></element-citation></ref></ref-list></back></article>